G
Gianluca Quintini
Publications - 2
Citations - 135
Gianluca Quintini is an academic researcher. The author has contributed to research in topics: Antibody & Vaccination. The author has an hindex of 2, co-authored 2 publications receiving 66 citations.
Papers
More filters
Posted ContentDOI
Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers
Lidia Oostvogels,Peter G. Kremsner,Andrea Kreidenweiss,Isabel Leroux-Roels,Geert Leroux-Roels,Arne Kroidl,Mirjam Schunk,Christoph Schindler,Jacobus J. Bosch,Rolf Fendel,Julian J. Gabor,Thirumalaisamy P. Velavan,P. Mann,Lisa Walz,Stefan Mueller,Oliver Schoenborn-Kellenberger,Thomas Verstraeten,Mariola Fotin-Mleczek,Dominik Vahrenhorst,Gianluca Quintini,Olaf-Oliver Wolz +20 more
TL;DR: Preliminary results in the subset of subjects who were enrolled with known SARS-CoV-2 seropositivity at baseline show that CVnCoV is also safe and well tolerated in this population, and is able to boost the pre-existing immune response even at low dose levels.
Journal ArticleDOI
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial.
Peter G. Kremsner,P. Mann,Arne Kroidl,Isabel Leroux-Roels,Christoph Schindler,Julian J. Gabor,Mirjam Schunk,Geert Leroux-Roels,Jacobus J. Bosch,Rolf Fendel,Andrea Kreidenweiss,Thirumalaisamy P. Velavan,Mariola Fotin-Mleczek,Stefan O. Mueller,Gianluca Quintini,Oliver Schönborn‑Kellenberger,Dominik Vahrenhorst,Thomas Verstraeten,Margarida Alves de Mesquita,Lisa Walz,Olaf‑Oliver Wolz,Lidia Oostvogels +21 more
TL;DR: In this article, the authors used the RNActive technology platform (CureVac N.V., Tubingen, Germany) to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding for a stabilised form of SARS-CoV-2 spike (S) protein encapsulated in lipid nanoparticles (LNP).